Cha Biotech Invests 55.25 Billion KRW in New Facility Expansion
[Asia Economy Reporter Lee Jung-yoon] Cha Biotech announced on the 20th that it has decided to invest 55.25 billion KRW in a new CDMO GMP facility.
Hot Picks Today
No Bacteria Detected in Arisu After 24 Hours of Repeated Drinking from a Tumbler
- "Not Even Expecting Gratitude, Just Hoping for No Complaints": Teachers' Sad Portrait on the Eve of Teacher's Day
- "Available Only in Korea": Pokémon Card Prices Surge 2,532% Due to Rarity, Becoming Investment Assets
- "He's Handsome, It's Such a Pity?"... Lawyer Responds to Bizarre 'Appearance Evaluation' of High School Girl Murder Suspect
- Police Officer Cycling on Day Off Rescues Woman Attempting to Jump from Hangju Bridge
This amount corresponds to 7.62% of the company's equity capital, and the investment period is until December 1, 2024. The company stated, "This is for the establishment of a global cell and gene therapy CDMO production facility and biobank."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
